← Back to patent-cliff list
RBD-7022
Tier C — Watch / tradeRBD-7022
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：PCSK9
Indications (approved)：谷甾醇血症, Hypercholesterolaemia, Hyperlipidaemia, 家族性混合型高脂血症
Regional status
US
-
EU
-
China
Phase III
2026-03-03
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of RBD-7022?
Approved indications include: 谷甾醇血症, Hypercholesterolaemia, Hyperlipidaemia, 家族性混合型高脂血症.
When does the RBD-7022 patent expire?
No public expiry year is available for RBD-7022 yet; this page updates once verified.
How do I get a quote for RBD-7022 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29